Positive Data on Glaxo & THRX Drug - Analyst Blog

By
A A A

GlaxoSmithKline ( GSK ) and Theravance, Inc. ( THRX ) recently announced data from four pivotal phase III studies conducted with their pipeline candidate, LAMA/LABA (UMEC/VI), for chronic obstructive pulmonary disease (COPD). LAMA/LABA is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).

While two studies compared the efficacy and safety of LAMA/LABA with VI, UMEC and placebo, the other two other studies compared the efficacy and safety of LAMA/LABA with Pfizer's ( PFE ) Spiriva. Spiriva is commonly used as a maintenance treatment for COPD. The four studies together enrolled over 4,000 COPD patients.

In both the placebo-controlled, 24-week, randomized, double-blind studies, LAMA/LABA showed a statistically significant benefit over VI, UMEC and placebo. In the first head-to-head comparison with Spiriva, LAMA/LABA showed a statistically significant improvement. However, in the second study, LAMA/LABA failed to do so although it demonstrated numerical difference.

Currently, a 52-week safety study and two replicate 12-week crossover exercise studies are ongoing for LAMA/LABA. Glaxo plans to submit regulatory applications for LAMA/LABA towards the end of 2012.  

Our Take

LAMA/LABA, if approved, will be positioned as a replacement for Advair, one of Glaxo's highest revenue earners with 2011 sales exceeding £5 billion. We note that Glaxo along with Theravance is also developing other COPD candidates including Relovair and MABA (GSK961081).

Earlier in May 2012, Glaxo had acquired 10,000,000 shares of Theravance for approximately $21.2887 per share. With this transaction, Glaxo increased its holding in Theravance to 26.7% from 18.3%. The increased holding by Glaxo reflects its confidence in the pipeline candidates.

We currently have Neutral recommendations on both Glaxo and Theravance. Both the stocks carry a Zacks #3 Rank (Hold rating) in the short run.


 
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
 
PFIZER INC (PFE): Free Stock Analysis Report
 
THERAVANCE INC (THRX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: GSK , PFE , THRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

88,363,013
  • $102.47 ▲ 2.72%
76,664,591
  • $16.60 ▲ 2.09%
75,156,840
  • $13.20 ▼ 5.71%
53,255,668
  • $40.68 ▼ 6.03%
49,564,657
  • $96.87 ▲ 2.63%
42,649,404
  • $9.26 ▲ 1.09%
37,436,329
  • $31.19 ▲ 5.05%
35,538,826
  • $28.28 ▲ 1.25%
As of 10/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com